NCT00798304

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 42 Days – 98 Days
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B vaccine in healthy infants.

Conditions

• Meningitis, Meningococcal

Interventions

Type	Name	Description
BIOLOGICAL	meningococcal B rLP2086 vaccine	vaccination
BIOLOGICAL	Routine age appropriate childhood vaccines	vaccination
BIOLOGICAL	meningococcal B rLP2086 vaccine	vaccination
BIOLOGICAL	Routine age appropriate childhood vaccines	vaccination
BIOLOGICAL	Routine age appropriate childhood vaccines	vaccination

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-06-01
• Completion: 2009-09-01
• First posted: 2008-11-26
• Last updated: 2014-11-26
• Results posted: 2014-11-26

Locations

7 sites across 1 country: Spain